| Literature DB >> 28659503 |
Lukas Bubendorf1, Sylvie Lantuejoul2,3, Adrianus J de Langen4, Erik Thunnissen5.
Abstract
The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require "tissue" management, which is best achieved by the interaction of all physicians involved.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28659503 DOI: 10.1183/16000617.0007-2017
Source DB: PubMed Journal: Eur Respir Rev ISSN: 0905-9180